|
Updated August 2, 2010
Stanley R. McCormick, MD, Matthew J. McCormick, BA, Patricia S. Grutkoski, PhD, Gregory S. Ducker, BA, Nilanjana Banerji, PhD, Rodney R. Higgins, PhD, John R. Mendiola, PhD, and John J. Reinartz, MD
Acquired mutations in the fms-like tyrosine kinase 3 gene (FLT3) adversely impact relapse risk after chemotherapy in patients with acute myeloid leukemia (AML). The FLT3 mutation status may differ at diagnosis and relapse, suggesting a potential role in chemoresistance, yet few reports have addressed the cytogenetic and pathologic correlates of FLT3 mutations in relapsed AML.
Full article
|
|
The Archives of Pathology & Laboratory Medicine,
the leading medical journal for pathologists worldwide, is seeking manuscripts
for publication, especially in the established fields of anatomic and
clinical pathology, as well as new technologies and laboratory management.
Color figures are published free of charge. Published articles also appear
full text and images on the Web.
Instructions for Authors (PDF, 242 KB)
Submit completed manuscripts to http://archivesofpathology.allentrack.net
If you have any questions, please contact the editorial office via e-mail or by phone (847-832-7400).
|
